



1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): McCormick et al.

Serial No.: 10/067,790

Group Art Unit: 1642

Filed: 2/8/2002

Examiner: YAEN, Christopher H.

Title: Self Antigen Vaccines for Treating B-Cell Lymphomas and Other Cancers

Attorney Docket No.: 42254

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

This Supplemental Information Disclosure Statement is submitted under 37 CFR 1.97(b), within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last.

Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references is that this is the closest art of which Applicant is aware. Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

I hereby certify that this Correspondence is being deposited with the United States Postal service with sufficient postage for first class mail in an envelope address to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or the correspondence is being facsimile transmitted to the USPTO, on the date indicated below.

Date of Deposit: 7 Jan 2005

Typed Name: Thomas Gallegos

Signature: Thomas Gallegos

Respectfully submitted,

Thomas Gallegos  
Thomas Gallegos, Reg. No. 32,692  
Attorney/Agent for Applicant(s)

Date: 7 Jan 2005

Telephone No. (707) 469-2307



Substitute for form 1449A/PTO

**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/067,790
Filing Date	2/8/2002
First Named Inventor	McCormick et al.
Art Unit	1642
Examiner Name	Yaen, Christopher H.
Attorney Docket Number	42254

Sheet

1

of

2

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		WO 94/08008	4/14/1994	HAWKINS, et al.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BENVENUTI and BURRONE, "Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined V <sub>L</sub> /V <sub>H</sub> determinants", <i>Gene Therapy</i> (2001) 8:1555-1561	
		CASPAR, et al., "Idiotypic vaccines for non-hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations", <i>Blood</i> (1997) 90(9):3699-3706	
		DE GRUIJL and CUIEL, "Cancer vaccine strategies get bigger and better", <i>Nature Medicine</i> (1999) 5(10):1124-1125	
		DONNELLY, "Cancer vaccine targets leukemia", <i>Nature Medicine</i> (2003) 9(11):1354-1356	
		EVANS and KAYE, "Vaccine therapy for cancer – fact or fiction?" <i>Q J Med.</i> (1999) 92:299-307	
		FITCHEN, et al., "Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response", <i>Vaccine</i> (1995) 13:1051-1057	
		GIRARD, et al., "Methodes d'etudes des virus", <i>Virologie Moleculaire</i> (1989), Chapter 2, pp. 61-65	
		HAKIM, et al., "A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines", <i>J. Immun.</i> (1996) 157(12):5503-5511	
		HENNECKE, et al., "Non-repetitive single-chain Fv linkers selected by selectively infective phage (SIP) technology", <i>Protein Engineering</i> (1998) 11(5):405-410	
		HSU, et al., "Tumor-Specific idotype vaccines in the treatment of patients with B-cell lymphoma – long-term results of a clinical trial", <i>Blood</i> (1997) 89(9):3129-3135	
		JERALA, et al., "Improved expression and evaluation of polyethyleneimine precipitation in isolation of recombinant cysteine proteinase inhibitor Stefin B", <i>Protein Expression and Purification</i> (1994) 5:65-69	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# **SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/067,790
Filing Date	2/8/2002
First Named Inventor	McCormick et al.
Art Unit	1642
Examiner Name	Yaen, Christopher H.
Attorney Docket Number	42254

Sheet

2

of

2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		KING, et al., "DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma", <i>Nature Medicine</i> (1998) 4(11):1281-1286	
		LANGEVELD, et al., "Effective induction of neutralizing antibodies with the amino terminus of VP2 of canine parvovirus as a synthetic peptide", <i>Vaccine</i> (1994) 12:1473-1480	
		STEMMER, et al., "Selection of an active single chain Fv antibody from a protein linker library prepared by enzymatic inverse PCR", <i>Biotech.</i> (1993) 14(2):256-265	
		TANG, et al., "Selection of linkers for a catalytic single-chain antibody using phage display technology" (1996) 271(26):15682-15686	
		TAVLADORAKI, et al., "A single-chain antibody fragment is functionally expressed in the cytoplasm of both <i>Escherichia coli</i> and transgenic plants", <i>European J. Biochem.</i> (1999) 262(2):617-624	
		TURNER, et al., "Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology", <i>J. Immun. Methods</i> (1997) 205(1):43-54	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.